---
schema_version: "secwatch.filing_event.v1"
accession: "0001798749-24-000052"
form_type: "8-K"
ticker: "JBIO"
cik: "0001798749"
company_name: "Jade Biosciences, Inc."
filed_at: "2024-10-10T23:59:59+00:00"
generated_at: "2026-05-30T16:47:59.954434+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Director Maha Katabi resigns from Aerovate board and committees effective Oct 6, 2024

## Summary
- Maha Katabi, Ph.D., resigned from the board, Audit Committee, and Compensation Committee.
- Resignation effective October 6, 2024, voluntary and not due to any disagreement with the company.
- Board expressed gratitude for Dr. Katabi's service and contributions.

## SEC filing metadata
- accession: 0001798749-24-000052
- form_type: 8-K
- ticker: JBIO
- cik: 0001798749
- company_name: Jade Biosciences, Inc.
- filed_at: 2024-10-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1798749/000179874924000052/0001798749-24-000052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1798749/000179874924000052/tmb-20241006x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001798749-24-000052
- JSON: https://secwatch.observer/filing/0001798749-24-000052.json
- Plain text: https://secwatch.observer/filing/0001798749-24-000052.txt

## Key facts
- Executive change
  Maha Katabi resigned as Director at Jade Biosciences, Inc..
  - Action: resigned
  - Role: Director
  source text: On October 6, 2024, Maha Katabi, Ph.D., provided notice of her resignation from the board of directors (the “Board”) of Aerovate Therapeutics, Inc. (the “Company”), effective as of October 6, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1798749/000179874924000052/0001798749-24-000052-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.